<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36512061</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>LATE-NC staging in routine neuropathologic diagnosis: an update.</ArticleTitle><Pagination><StartPage>159</StartPage><EndPage>173</EndPage><MedlinePgn>159-173</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-022-02524-2</ELocationID><Abstract><AbstractText>An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer's disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Peter T</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>University of Kentucky, Rm 575 Todd Building, Lexington, KY, USA. pnels2@email.uky.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cykowski</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alafuzoff</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Uppsala University, Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arfanakis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Illinois Institute of Technology, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Attems</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brayne</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corrada</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dugger</LastName><ForeName>Brittany N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>University of California, Davis, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Margaret E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Northwestern University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grothe</LastName><ForeName>Michel J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Unidad de Trastornos del Movimiento, Servicio de Neurolog&#xed;a Y Neurofisiolog&#xed;a Cl&#xed;nica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Roc&#xed;o/CSIC/Universidad de Sevilla, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halliday</LastName><ForeName>Glenda M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hokkanen</LastName><ForeName>Suvi R K</ForeName><Initials>SRK</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jellinger</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Clinical Neurobiology, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keene</LastName><ForeName>C Dirk</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouri</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine Program, University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leverenz</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>The Cleveland Clinic, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latimer</LastName><ForeName>Caitlin S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>The University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qinwen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>University of Utah, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McAleese</LastName><ForeName>Kirsty E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Newcastle University, Newcastle Upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrick</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myllykangas</LastName><ForeName>Liisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Helsinki and Helsinki University Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nag</LastName><ForeName>Sukriti</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neltner</LastName><ForeName>Janna H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>University of Kentucky, Rm 575 Todd Building, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newell</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>University of California San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tokyo Metropolitan Geriatric Hospital &amp; Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajjadi</LastName><ForeName>S Ahmad</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>University of California, Irvine, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwetye</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Washington University, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teich</LastName><ForeName>Andrew F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathoogy, and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, University Hospital Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tom&#xe9;</LastName><ForeName>Sandra O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Laboratory for Neuropathology, Department of Imaging and Pathoogy, and Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shih-Hsiu J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Duke University, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>University of Texas Southwestern Medical Center, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>New York University Grossman School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hyun-Sik</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, BostonBoston, MAMA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Mayo Clinic, Jacksonville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of T&#xfc;bingen and DZNE T&#xfc;bingen, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG067482</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066512</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG054449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0601022</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 AG062706</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG060882</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG064233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG066509</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072972</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG069052</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072946</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 NS118584</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G9901400</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000723354">limbic-predominant age-related TDP-43 encephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aging</Keyword><Keyword MajorTopicYN="N">Dementia</Keyword><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">Hippocampal sclerosis</Keyword><Keyword MajorTopicYN="N">NCI</Keyword><Keyword MajorTopicYN="N">Neuroanatomy</Keyword><Keyword MajorTopicYN="N">Processes</Keyword><Keyword MajorTopicYN="N">Stages</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>E.B.L., D.W.D., M.N., D.R.T., G.H., G.G.K., and P.T.N. are members of the Editorial Board of <i>Acta Neuropathologica</i> and J.A. is the Editor-in-Chief of <i>Acta Neuropathologica</i>, but none of the coauthors were involved in the Editorial handling if this article. D.R.T. received speaker honorary from Novartis Pharma AG (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium), and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>13</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36512061</ArticleId><ArticleId IdType="pmc">PMC9849315</ArticleId><ArticleId IdType="doi">10.1007/s00401-022-02524-2</ArticleId><ArticleId IdType="pii">10.1007/s00401-022-02524-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>(2022) LATE 2022 Webinar, 11 February https://www.nia.nih.gov/research/dn/late-2022. Accessed 1 Nov 2022</Citation></Reference><Reference><Citation>Agirre-Beitia G, Moreno-Estebanez A, Gonzalez-Pinto Gonzalez T, Melgar Jimenez B, Campos Rodriguez I, Cabral Martinez L, et al. FOSMN: a possible TDP-43 proteinopathy to consider in a patient with facial sensory symptoms. Neurol Clin Pract. 2020;10:e47&#x2013;e50. doi: 10.1212/CPJ.0000000000000753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/CPJ.0000000000000753</ArticleId><ArticleId IdType="pmc">PMC7717637</ArticleId><ArticleId IdType="pubmed">33299678</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Leurgans SE, James BD, Barnes LL, Mehta RI, Dams-O'Connor K, et al. Association of traumatic brain injury with and without loss of consciousness with neuropathologic outcomes in community-dwelling older persons. JAMA Netw Open. 2022;5:e229311. doi: 10.1001/jamanetworkopen.2022.9311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.9311</ArticleId><ArticleId IdType="pmc">PMC9047640</ArticleId><ArticleId IdType="pubmed">35476062</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal S, Yu L, Nag S, Arfanakis K, Barnes LL, Bennett DA, et al. The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer&#x2019;s dementia in older persons. Acta Neuropathol Commun. 2021;9:156. doi: 10.1186/s40478-021-01260-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01260-0</ArticleId><ArticleId IdType="pmc">PMC8466680</ArticleId><ArticleId IdType="pubmed">34563269</ArticleId></ArticleIdList></Reference><Reference><Citation>Alafuzoff I, Pikkarainen M, Neumann M, Arzberger T, Al-Sarraj S, Bodi I, et al. Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. J Neural Transm (Vienna) 2015;122:957&#x2013;972. doi: 10.1007/s00702-014-1304-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-014-1304-1</ArticleId><ArticleId IdType="pubmed">25239189</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Ahmed Z, Zehr C, Dickson DW. Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol (Berl) 2007;113:245&#x2013;252. doi: 10.1007/s00401-006-0183-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0183-4</ArticleId><ArticleId IdType="pmc">PMC1794627</ArticleId><ArticleId IdType="pubmed">17195931</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61:435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R, et al. Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP type A. Acta Neuropathol. 2015;129:53&#x2013;64. doi: 10.1007/s00401-014-1358-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1358-z</ArticleId><ArticleId IdType="pmc">PMC4282950</ArticleId><ArticleId IdType="pubmed">25367383</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T. Significance and limitation of the pathological classification of TDP-43 proteinopathy. Neuropathology. 2014;34:578&#x2013;588. doi: 10.1111/neup.12138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12138</ArticleId><ArticleId IdType="pubmed">25196969</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, et al. Phosphorylated TDP-43 in Alzheimer&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 2009;117:125&#x2013;136. doi: 10.1007/s00401-008-0480-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0480-1</ArticleId><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol. 2013;126:51&#x2013;57. doi: 10.1007/s00401-013-1110-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1110-0</ArticleId><ArticleId IdType="pmc">PMC3691299</ArticleId><ArticleId IdType="pubmed">23604587</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G, et al. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141:159&#x2013;172. doi: 10.1007/s00401-020-02255-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02255-2</ArticleId><ArticleId IdType="pmc">PMC7847437</ArticleId><ArticleId IdType="pubmed">33399945</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayaki T, Murata K, Kanazawa N, Uruha A, Ohmura K, Sugie K, et al. Myositis with sarcoplasmic inclusions in Nakajo-Nishimura syndrome: a genetic inflammatory myopathy. Neuropathol Appl Neurobiol. 2020;46:579&#x2013;587. doi: 10.1111/nan.12614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12614</ArticleId><ArticleId IdType="pubmed">32144790</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16:203&#x2013;212. doi: 10.1097/00002093-200210000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002093-200210000-00001</ArticleId><ArticleId IdType="pubmed">12468894</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins BL, Vinters HV, Love S, Wilcock DM, Grinberg LT, Schneider JA, et al. Brain arteriolosclerosis. Acta Neuropathol. 2020 doi: 10.1007/s00401-020-02235-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02235-6</ArticleId><ArticleId IdType="pmc">PMC8503820</ArticleId><ArticleId IdType="pubmed">33098484</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Wang T, Yu L, Wilson RS, Dawe R, Arfanakis K, et al. To what degree is late life cognitive decline driven by age-relatedneuropathologies? Brain. 2021 doi: 10.1093/brain/awab092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab092</ArticleId><ArticleId IdType="pmc">PMC8370442</ArticleId><ArticleId IdType="pubmed">33742668</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, et al. Attributable risk of Alzheimer&#x2019;s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85:114&#x2013;124. doi: 10.1002/ana.25380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25380</ArticleId><ArticleId IdType="pubmed">30421454</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson&#x2019;s disease-related pathology. Cell Tissue Res. 2004;318:121&#x2013;134. doi: 10.1007/s00441-004-0956-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-004-0956-9</ArticleId><ArticleId IdType="pubmed">15338272</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960&#x2013;969. doi: 10.1097/NEN.0b013e318232a379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38. doi: 10.1002/ana.23937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Buciuc M, Martin PR, Tosakulwong N, Murray ME, Petrucelli L, Senjem ML, et al. TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. Neuroimage Clin. 2022;34:102954. doi: 10.1016/j.nicl.2022.102954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2022.102954</ArticleId><ArticleId IdType="pmc">PMC8850800</ArticleId><ArticleId IdType="pubmed">35168140</ArticleId></ArticleIdList></Reference><Reference><Citation>Buciuc M, Whitwell JL, Baker MC, Rademakers R, Dickson DW, Josephs KA. Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. Neuropathol Appl Neurobiol: 2021 doi: 10.1111/nan.12727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12727</ArticleId><ArticleId IdType="pmc">PMC8576062</ArticleId><ArticleId IdType="pubmed">33969528</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5&#x2013;22. doi: 10.1007/s00401-007-0237-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0237-2</ArticleId><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlos AF, Tosakulwong N, Weigand SD, Boeve BF, Knopman DS, Petersen RC, et al. Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathol. 2022 doi: 10.1007/s00401-022-02434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02434-3</ArticleId><ArticleId IdType="pubmed">35536384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SH, Choi SM, Kim BC, Song WY, Kim HS, Lee KH. An autopsy-proven case of limbic-predominant age-related TDP-43 encephalopathy. Yonsei Med J. 2020;61:731&#x2013;735. doi: 10.3349/ymj.2020.61.8.731.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2020.61.8.731</ArticleId><ArticleId IdType="pmc">PMC7393298</ArticleId><ArticleId IdType="pubmed">32734738</ArticleId></ArticleIdList></Reference><Reference><Citation>Chompoopong P, Milone M, Niu Z, Cui G, Mer G, Liewluck T. A novel missense HNRNPA1 variant in the PY-NLS domain in a patient with late-onset distal myopathy. Neuromuscul Disord. 2022;32:521&#x2013;526. doi: 10.1016/j.nmd.2022.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2022.03.009</ArticleId><ArticleId IdType="pubmed">35550112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chornenkyy Y, Fardo DW, Nelson PT. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Lab Invest. 2019;99:993&#x2013;1007. doi: 10.1038/s41374-019-0196-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-019-0196-y</ArticleId><ArticleId IdType="pmc">PMC6609463</ArticleId><ArticleId IdType="pubmed">30742063</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J, Sabbagh MN, Bondi MW, Hansen L, Alford MF, Masliah E, et al. Hippocampal sclerosis contributes to dementia in the elderly. Neurology. 1997;48:154&#x2013;160. doi: 10.1212/WNL.48.1.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.48.1.154</ArticleId><ArticleId IdType="pubmed">9008511</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Arumanayagam AS, Powell SZ, Rivera AL, Abner EL, Roman GC, et al. Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies. Acta Neuropathol. 2022 doi: 10.1007/s00401-022-02416-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02416-5</ArticleId><ArticleId IdType="pmc">PMC9038848</ArticleId><ArticleId IdType="pubmed">35366087</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS, Raby S, Foulds PG, Robinson A, Thompson JC, Sikkink S, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer&#x2019;s disease, late onset Alzheimer&#x2019;s disease and Down&#x2019;s syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 2011;122:703&#x2013;713. doi: 10.1007/s00401-011-0879-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0879-y</ArticleId><ArticleId IdType="pubmed">21968532</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E, et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (&gt; or = 80 years of age) humans. Acta Neuropathol. 1994;88:212&#x2013;221. doi: 10.1007/BF00293396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00293396</ArticleId><ArticleId IdType="pubmed">7810292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Josephs KA, Amador-Ortiz C. TDP-43 in differential diagnosis of motor neuron disorders. Acta Neuropathol. 2007;114:71&#x2013;79. doi: 10.1007/s00401-007-0234-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0234-5</ArticleId><ArticleId IdType="pubmed">17569066</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Rademakers R, Nicholson AM, Schneider JA, Yu L, Bennett DA. The TMEM106B locus and TDP-43 pathology in older persons without FTLD. Neurology. 2015;85:1354&#x2013;1355. doi: 10.1212/01.wnl.0000472918.79256.a9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000472918.79256.a9</ArticleId><ArticleId IdType="pmc">PMC5990310</ArticleId><ArticleId IdType="pubmed">26459943</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugan AJ, Nelson PT, Katsumata Y, Shade LMP, Boehme KL, Teylan MA, et al. Analysis of genes (TMEM106B, GRN, ABCC9, KCNMB2, and APOE) implicated in risk for LATE-NC and hippocampal sclerosis provides pathogenetic insights: a retrospective genetic association study. Acta Neuropathol Commun. 2021;9:152. doi: 10.1186/s40478-021-01250-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01250-2</ArticleId><ArticleId IdType="pmc">PMC8442328</ArticleId><ArticleId IdType="pubmed">34526147</ArticleId></ArticleIdList></Reference><Reference><Citation>Fearon C, Koch M-L, Hefferman J, Heeney C, Lorigan J, Beausang A, et al. Phosphorylation-dependent TDP-43 antibodies: validation in a neurodegenerative brain bank cohort. J Alzheimer&#x2019;s Parkinsonism Dement. 2019;3:1&#x2013;4.</Citation></Reference><Reference><Citation>Flanagan ME, Cholerton B, Latimer CS, Hemmy LS, Edland SD, Montine KS, et al. TDP-43 neuropathologic associations in the nun study and the honolulu-asia aging study. J Alzheimers Dis. 2018;66:1549&#x2013;1558. doi: 10.3233/JAD-180162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180162</ArticleId><ArticleId IdType="pmc">PMC6382067</ArticleId><ArticleId IdType="pubmed">30452409</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest SL, Wagner S, Kim A, Kovacs GG. Association of glial tau pathology and LATE-NC in the ageing brain. Neurobiol Aging. 2022;119:77&#x2013;88. doi: 10.1016/j.neurobiolaging.2022.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2022.07.010</ArticleId><ArticleId IdType="pubmed">35977443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthreaux KM, Teylan MA, Katsumata Y, Mock C, Culhane JE, Chen YC, et al. Limbic-predominant age-related TDP-43 encephalopathy: medical and pathologic factors associated with comorbid hippocampal sclerosis. Neurology. 2022;98:e1422&#x2013;e1433. doi: 10.1212/WNL.0000000000200001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200001</ArticleId><ArticleId IdType="pmc">PMC8992604</ArticleId><ArticleId IdType="pubmed">35121671</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Robinson JL, Malunda JA, Xie SX, Clark CM, Kwong LK, et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol. 2010;67:1238&#x2013;1250. doi: 10.1001/archneurol.2010.254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.254</ArticleId><ArticleId IdType="pmc">PMC3050578</ArticleId><ArticleId IdType="pubmed">20937952</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens J, Vanmechelen E, Trojanowski JQ, Lee VM, Van Broeckhoven C, van der Zee J, et al. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathol Commun. 2015;3:15. doi: 10.1186/s40478-015-0195-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0195-1</ArticleId><ArticleId IdType="pmc">PMC4380254</ArticleId><ArticleId IdType="pubmed">25853864</ArticleId></ArticleIdList></Reference><Reference><Citation>Grothe MJ, Moscoso A, Silva-Rodriguez J, Lange C, Nho K, Saykin AJ, et al. Differential diagnosis of amnestic dementia patients based on an FDG-PET signature of autopsy-confirmed LATE-NC. Alzheimers Dement. 2022 doi: 10.1002/alz.12763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12763</ArticleId><ArticleId IdType="pubmed">35971593</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison WT, Lusk JB, Liu B, Ervin JF, Johnson KG, Green CL, et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is independently associated with dementia and strongly associated with arteriolosclerosis in the oldest-old. Acta Neuropathol. 2021 doi: 10.1007/s00401-021-02360-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02360-w</ArticleId><ArticleId IdType="pmc">PMC8816525</ArticleId><ArticleId IdType="pubmed">34415381</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Akiyama H, Nonaka T, Mori H, Hashimoto T, et al. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain. 2007;130:1386&#x2013;1394. doi: 10.1093/brain/awm065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm065</ArticleId><ArticleId IdType="pubmed">17439983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatanpaa KJ, Raisanen JM, Herndon E, Burns DK, Foong C, Habib AA, et al. Hippocampal sclerosis in dementia, epilepsy, and ischemic injury: differential vulnerability of hippocampal subfields. J Neuropathol Exp Neurol. 2014;73:136&#x2013;142. doi: 10.1097/OPX.0000000000000170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/OPX.0000000000000170</ArticleId><ArticleId IdType="pmc">PMC4076969</ArticleId><ArticleId IdType="pubmed">24423638</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer&#x2019;s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294. doi: 10.1016/j.brainres.2007.09.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.09.048</ArticleId><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkanen SRK, Hunter S, Polvikoski TM, Keage HAD, Minett T, Matthews FE, Group CCS et al. Hippocampal sclerosis, hippocampal neuron loss patterns and TDP-43 in the aged population. Brain Pathol. 2018;28:548&#x2013;559. doi: 10.1111/bpa.12556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12556</ArticleId><ArticleId IdType="pmc">PMC6099461</ArticleId><ArticleId IdType="pubmed">28833898</ArticleId></ArticleIdList></Reference><Reference><Citation>Hokkanen SRK, Kero M, Kaivola K, Hunter S, Keage HAD, Kiviharju A, et al. Putative risk alleles for LATE-NC with hippocampal sclerosis in population-representative autopsy cohorts. Brain Pathol. 2020;30:364&#x2013;372. doi: 10.1111/bpa.12773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12773</ArticleId><ArticleId IdType="pmc">PMC7065086</ArticleId><ArticleId IdType="pubmed">31376286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC, et al. Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta Neuropathol. 2008;116:215&#x2013;220. doi: 10.1007/s00401-008-0400-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0400-4</ArticleId><ArticleId IdType="pmc">PMC3404722</ArticleId><ArticleId IdType="pubmed">18592255</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Zhou Y, Tu L, Ba Z, Huang J, Huang N, et al. TDP-43: from Alzheimer&#x2019;s disease to limbic-predominant age-related TDP-43 encephalopathy. Front Mol Neurosci. 2020;13:26. doi: 10.3389/fnmol.2020.00026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00026</ArticleId><ArticleId IdType="pmc">PMC7059763</ArticleId><ArticleId IdType="pubmed">32180703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter S, Hokkanen SRK, Keage HAD, Fleming J, Minett T, Polvikoski T, Cambridge City over 75s Cohort c et al. TDP-43 related neuropathologies and phosphorylation state: associations with age and clinical Dementia in the Cambridge city over-75s cohort. J Alzheimers Dis. 2020;75:337&#x2013;350. doi: 10.3233/JAD-191093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-191093</ArticleId><ArticleId IdType="pubmed">32280087</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichimata S, Yoshida K, Visanji NP, Lang AE, Nishida N, Kovacs GG. Patterns of mixed pathologies in Down syndrome. J Alzheimers Dis. 2022;87:595&#x2013;607. doi: 10.3233/JAD-215675.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-215675</ArticleId><ArticleId IdType="pubmed">35311708</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, et al. Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173:182&#x2013;194. doi: 10.2353/ajpath.2008.080003.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.080003</ArticleId><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighodaro ET, Jicha GA, Schmitt FA, Neltner JH, Abner EL, Kryscio RJ, et al. Hippocampal sclerosis of aging can be segmental: two cases and review of the literature. J Neuropathol Exp Neurol. 2015;74:642&#x2013;652. doi: 10.1097/NEN.0000000000000204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0000000000000204</ArticleId><ArticleId IdType="pmc">PMC4539239</ArticleId><ArticleId IdType="pubmed">26083567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ighodaro ET, Nelson PT, Kukull WA, Schmitt FA, Abner EL, Caban-Holt A, et al. Challenges and considerations related to studying dementia in blacks/African Americans. J Alzheimers Dis. 2017;60:1&#x2013;10. doi: 10.3233/JAD-170242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170242</ArticleId><ArticleId IdType="pmc">PMC5889715</ArticleId><ArticleId IdType="pubmed">28731440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ihara R, Vincent BD, Baxter MR, Franklin EE, Hassenstab JJ, Xiong C, et al. Relative neuron loss in hippocampal sclerosis of aging and Alzheimer&#x2019;s disease. Ann Neurol. 2018;84:741&#x2013;753. doi: 10.1002/ana.25344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25344</ArticleId><ArticleId IdType="pmc">PMC6373729</ArticleId><ArticleId IdType="pubmed">30246887</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamerlan A, An SSA. The influence of Abeta-dependent and independent pathways on TDP-43 proteinopathy in Alzheimer&#x2019;s disease: a possible connection to LATE-NC. Neurobiol Aging. 2020;95:161&#x2013;167. doi: 10.1016/j.neurobiolaging.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.06.020</ArticleId><ArticleId IdType="pubmed">32814257</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain. 2016;139:2983&#x2013;2993. doi: 10.1093/brain/aww224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA. Hippocampal sclerosis: a common pathological feature of dementia in very old humans. Acta Neuropathol. 1994;88:599. doi: 10.1007/BF00296500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00296500</ArticleId><ArticleId IdType="pubmed">7879610</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Trojanowski JQ, Smith DH. Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans. Acta Neuropathol. 2011;122:715&#x2013;726. doi: 10.1007/s00401-011-0909-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0909-9</ArticleId><ArticleId IdType="pmc">PMC3979333</ArticleId><ArticleId IdType="pubmed">22101322</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T, et al. LATE to the PART-y. Brain. 2019;142:e47. doi: 10.1093/brain/awz224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz224</ArticleId><ArticleId IdType="pmc">PMC6736234</ArticleId><ArticleId IdType="pubmed">31359030</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol. 2019;137:227&#x2013;238. doi: 10.1007/s00401-018-1951-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1951-7</ArticleId><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, et al. Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:441&#x2013;450. doi: 10.1007/s00401-013-1211-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, et al. Updated TDP-43 in Alzheimer&#x2019;s disease staging scheme. Acta Neuropathol. 2016;131:571&#x2013;585. doi: 10.1007/s00401-016-1537-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1537-1</ArticleId><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol. 2009;118:349&#x2013;358. doi: 10.1007/s00401-009-0547-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0547-7</ArticleId><ArticleId IdType="pmc">PMC3044602</ArticleId><ArticleId IdType="pubmed">19455346</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008;70:1850&#x2013;1857. doi: 10.1212/01.wnl.0000304041.09418.b1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000304041.09418.b1</ArticleId><ArticleId IdType="pmc">PMC2779031</ArticleId><ArticleId IdType="pubmed">18401022</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer&#x2019;s disease impact clinical features. Ann Neurol. 2015;78:697&#x2013;709. doi: 10.1002/ana.24493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24493</ArticleId><ArticleId IdType="pmc">PMC4623932</ArticleId><ArticleId IdType="pubmed">26224156</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:811&#x2013;824. doi: 10.1007/s00401-014-1269-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadokura A, Yamazaki T, Kakuda S, Makioka K, Lemere CA, Fujita Y, et al. Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration. Neurosci Lett. 2009;463:87&#x2013;92. doi: 10.1016/j.neulet.2009.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.06.024</ArticleId><ArticleId IdType="pubmed">19539703</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology. 2009;29:566&#x2013;573. doi: 10.1111/j.1440-1789.2009.01017.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1789.2009.01017.x</ArticleId><ArticleId IdType="pubmed">19422539</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Fardo DW, Kukull WA, Nelson PT. Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer&#x2019;s disease and cerebrovascular disease pathologies. Acta Neuropathol Commun. 2018;6:142. doi: 10.1186/s40478-018-0641-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0641-y</ArticleId><ArticleId IdType="pmc">PMC6299605</ArticleId><ArticleId IdType="pubmed">30567576</ArticleId></ArticleIdList></Reference><Reference><Citation>Keage HA, Hunter S, Matthews FE, Ince PG, Hodges J, Hokkanen SR, et al. TDP-43 pathology in the population: prevalence and associations with dementia and age. J Alzheimers Dis. 2014;42:641&#x2013;650. doi: 10.3233/JAD-132351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-132351</ArticleId><ArticleId IdType="pubmed">25170584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kero M, Raunio A, Polvikoski T, Tienari PJ, Paetau A, Myllykangas L. Hippocampal sclerosis in the oldest old: a finnish population-based study. J Alzheimers Dis. 2018;63:263&#x2013;272. doi: 10.3233/JAD-171068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-171068</ArticleId><ArticleId IdType="pmc">PMC5900558</ArticleId><ArticleId IdType="pubmed">29614661</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein HU, Trumpff C, Yang HS, Lee AJ, Picard M, Bennett DA, et al. Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer&#x2019;s disease brain. Mol Neurodegener. 2021;16:75. doi: 10.1186/s13024-021-00495-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00495-8</ArticleId><ArticleId IdType="pmc">PMC8572491</ArticleId><ArticleId IdType="pubmed">34742335</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokubo Y, Morimoto S, Sasaki R, Hasegawa M, Ishiura H, Tsuji S, et al. An immigrant family with Kii amyotrophic lateral sclerosis/parkinsonism-dementia complex. Neurol Sci. 2022;43:1423&#x2013;1425. doi: 10.1007/s10072-021-05737-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05737-7</ArticleId><ArticleId IdType="pubmed">34779964</ArticleId></ArticleIdList></Reference><Reference><Citation>Koper MJ, Tome SO, Gawor K, Belet A, Van Schoor E, Schaeverbeke J, et al. LATE-NC aggravates GVD-mediated necroptosis in Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2022;10:128. doi: 10.1186/s40478-022-01432-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-022-01432-6</ArticleId><ArticleId IdType="pmc">PMC9441100</ArticleId><ArticleId IdType="pubmed">36057624</ArticleId></ArticleIdList></Reference><Reference><Citation>Koper MJ, Van Schoor E, Ospitalieri S, Vandenberghe R, Vandenbulcke M, von Arnim CAF, et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer&#x2019;s disease. Acta Neuropathol. 2020;139:463&#x2013;484. doi: 10.1007/s00401-019-02103-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02103-y</ArticleId><ArticleId IdType="pubmed">31802237</ArticleId></ArticleIdList></Reference><Reference><Citation>Koyano S, Yagishita S, Tada M, Doi H, Uchihara T, Tanaka F. Parallel appearance of polyglutamine and transactivation-responsive DNA-binding protein 43 and their complementary subcellular localization in brains of patients with spinocerebellar ataxia type 2. J Neuropathol Exp Neurol. 2022;81:535&#x2013;544. doi: 10.1093/jnen/nlac032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlac032</ArticleId><ArticleId IdType="pubmed">35511239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Irwin DJ, Walker AK, Xu Y, Riddle DM, Trojanowski JQ, et al. Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins. Acta Neuropathol Commun. 2014;2:33. doi: 10.1186/2051-5960-2-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-33</ArticleId><ArticleId IdType="pmc">PMC4023626</ArticleId><ArticleId IdType="pubmed">24690345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachner C, Day GS, Camsari GB, Kouri N, Ertekin-Taner N, Boeve BF et al (2022) Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest- Old. J Alzheimers Dis. 90(1):405-417. 10.3233/JAD-220440</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9661335</ArticleId><ArticleId IdType="pubmed">36213996</ArticleId></ArticleIdList></Reference><Reference><Citation>Latimer CS, Burke BT, Liachko NF, Currey HN, Kilgore MD, Gibbons LE, et al. Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun. 2019;7:91. doi: 10.1186/s40478-019-0743-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0743-1</ArticleId><ArticleId IdType="pmc">PMC6556006</ArticleId><ArticleId IdType="pubmed">31174609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB. Integrated neurodegenerative disease autopsy diagnosis. Acta Neuropathol. 2018;135:643&#x2013;646. doi: 10.1007/s00401-018-1827-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1827-x</ArticleId><ArticleId IdType="pmc">PMC6186396</ArticleId><ArticleId IdType="pubmed">29502201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ, Neumann M. TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system. Acta Neuropathol. 2008;115:305&#x2013;311. doi: 10.1007/s00401-007-0331-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0331-5</ArticleId><ArticleId IdType="pubmed">18087705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65&#x2013;78. doi: 10.1007/s00401-017-1679-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1679-9</ArticleId><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Agustin CM, Tsuang D, Peskind ER, Edland SD, Nochlin D, et al. Clinical and neuropathological characteristics of hippocampal sclerosis: a community-based study. Arch Neurol. 2002;59:1099&#x2013;1106. doi: 10.1001/archneur.59.7.1099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.7.1099</ArticleId><ArticleId IdType="pubmed">12117357</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Lipton AM. Clinical aspects of hippocampal sclerosis. Handb Clin Neurol. 2008;89:565&#x2013;567. doi: 10.1016/S0072-9752(07)01252-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0072-9752(07)01252-3</ArticleId><ArticleId IdType="pubmed">18631778</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Castanedes-Casey M, Dickson DW. Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol. 2009;68:1167&#x2013;1176. doi: 10.1097/NEN.0b013e3181baacec.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181baacec</ArticleId><ArticleId IdType="pmc">PMC2783428</ArticleId><ArticleId IdType="pubmed">19816201</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Kofler J, Chang Y, Berman SB, Becker JT, Sweet RA, et al. Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. Ann Clin Transl Neurol. 2020;7:1546&#x2013;1556. doi: 10.1002/acn3.51135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51135</ArticleId><ArticleId IdType="pmc">PMC7480925</ArticleId><ArticleId IdType="pubmed">32735084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 2014;127:347&#x2013;357. doi: 10.1007/s00401-013-1232-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1232-4</ArticleId><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 2017;134:79&#x2013;96. doi: 10.1007/s00401-017-1716-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1716-8</ArticleId><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol. 2020;139:83&#x2013;98. doi: 10.1007/s00401-019-02070-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02070-4</ArticleId><ArticleId IdType="pubmed">31501924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113. doi: 10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1&#x2013;4. doi: 10.1007/s00401-009-0612-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0612-2</ArticleId><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 2009;117:15&#x2013;18. doi: 10.1007/s00401-008-0460-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0460-5</ArticleId><ArticleId IdType="pmc">PMC2710877</ArticleId><ArticleId IdType="pubmed">19015862</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, Johnson M, Koss D, Thomas AJ, et al. Concomitant LATE-NC in Alzheimer&#x2019;s disease is not associated with increased tau or amyloid-beta pathological burden. Neuropathol Appl Neurobiol. 2020;46:722&#x2013;734. doi: 10.1111/nan.12664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12664</ArticleId><ArticleId IdType="pubmed">32896913</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131:75&#x2013;86. doi: 10.1007/s00401-015-1515-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1515-z</ArticleId><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69:918&#x2013;929. doi: 10.1097/NEN.0b013e3181ee7d85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181ee7d85</ArticleId><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Melikyan ZA, Corrada MM, Leiby AM, Sajjadi SA, Bukhari S, Montine TJ, et al. Cognitive resilience to three dementia-related neuropathologies in an oldest-old man: a case report from the 90+ study. Neurobiol Aging. 2022;116:12&#x2013;15. doi: 10.1016/j.neurobiolaging.2022.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2022.03.009</ArticleId><ArticleId IdType="pmc">PMC9733494</ArticleId><ArticleId IdType="pubmed">35526514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol MO, van Rooij JGJ, Wong TH, Melhem S, Verkerk A, Kievit AJA, et al. Underlying genetic variation in familial frontotemporal dementia: sequencing of 198 patients. Neurobiol Aging. 2021;97:148e149&#x2013;148e116. doi: 10.1016/j.neurobiolaging.2020.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2020.07.014</ArticleId><ArticleId IdType="pubmed">32843152</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Corrada MM, Kawas C, Bukhari S, White L, Tian L, et al. Association of cognition and dementia with neuropathologic changes of Alzheimer disease and other conditions in the oldest-old. Neurology. 2022 doi: 10.1212/WNL.0000000000200832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000200832</ArticleId><ArticleId IdType="pmc">PMC9519247</ArticleId><ArticleId IdType="pubmed">35705500</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami A, Koga S, Sekiya H, Oskarsson B, Boylan K, Petrucelli L, et al. Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology. Brain Pathol. 2022 doi: 10.1111/bpa.13100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.13100</ArticleId><ArticleId IdType="pmc">PMC9616086</ArticleId><ArticleId IdType="pubmed">35715944</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Bieniek KF, Banks Greenberg M, DeJesus-Hernandez M, Rutherford NJ, van Blitterswijk M, et al. Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72. Acta Neuropathol. 2013;126:545&#x2013;554. doi: 10.1007/s00401-013-1161-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1161-2</ArticleId><ArticleId IdType="pmc">PMC3926101</ArticleId><ArticleId IdType="pubmed">23922030</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross OA, et al. Differential clinicopathologic and genetic features of late-onset amnestic dementias. Acta Neuropathol. 2014;128:411&#x2013;421. doi: 10.1007/s00401-014-1302-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1302-2</ArticleId><ArticleId IdType="pmc">PMC4412022</ArticleId><ArticleId IdType="pubmed">24899141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Barnes LL, Yu L, Wilson RS, Bennett DA, Schneider JA. Limbic-predominant age-related TDP-43 encephalopathy in Black and White decedents. Neurology. 2020;95:e2056&#x2013;e2064. doi: 10.1212/WNL.0000000000010602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010602</ArticleId><ArticleId IdType="pmc">PMC7713750</ArticleId><ArticleId IdType="pubmed">32759188</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer&#x2019;s disease. Acta Neuropathol Commun. 2018;6:33. doi: 10.1186/s40478-018-0531-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0531-3</ArticleId><ArticleId IdType="pmc">PMC5928580</ArticleId><ArticleId IdType="pubmed">29716643</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol. 2015;77:942&#x2013;952. doi: 10.1002/ana.24388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24388</ArticleId><ArticleId IdType="pmc">PMC4447563</ArticleId><ArticleId IdType="pubmed">25707479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA. TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology. 2017;88:653&#x2013;660. doi: 10.1212/WNL.0000000000003610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003610</ArticleId><ArticleId IdType="pmc">PMC5317379</ArticleId><ArticleId IdType="pubmed">28087828</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Di Lorenzo Alho AT, Bazan Conceicao Amaral C, Leite REP, Nitrini R, Jacob-Filho W, et al. Prevalence of transactive response DNA-binding protein 43 (TDP-43) proteinopathy in cognitively normal older adults: systematic review and meta-analysis. Neuropathol Appl Neurobiol. 2018;44:286&#x2013;297. doi: 10.1111/nan.12430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12430</ArticleId><ArticleId IdType="pmc">PMC5902737</ArticleId><ArticleId IdType="pubmed">28793370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento C, Suemoto CK, Rodriguez RD, Alho AT, Leite RP, Farfel JM, et al. Higher prevalence of TDP-43 proteinopathy in cognitively normal asians: a clinicopathological study on a multiethnic sample. Brain Pathol. 2016;26:177&#x2013;185. doi: 10.1111/bpa.12296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12296</ArticleId><ArticleId IdType="pmc">PMC4751066</ArticleId><ArticleId IdType="pubmed">26260327</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Patel E, Anderson S, Wilcock DM, Kryscio RJ, et al. The amygdala as a locus of pathologic misfolding in neurodegenerative diseases. J Neuropathol Exp Neurol. 2018;77:2&#x2013;20. doi: 10.1093/jnen/nlx099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx099</ArticleId><ArticleId IdType="pmc">PMC5901077</ArticleId><ArticleId IdType="pubmed">29186501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, et al. Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol. 2010;20:66&#x2013;79. doi: 10.1111/j.1750-3639.2008.00244.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00244.x</ArticleId><ArticleId IdType="pmc">PMC2864342</ArticleId><ArticleId IdType="pubmed">19021630</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#x2013;381. doi: 10.1097/NEN.0b013e31825018f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Brayne C, Flanagan ME, Abner EL, Agrawal S, Attems J, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer&#x2019;s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022 doi: 10.1007/s00401-022-02444-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02444-1</ArticleId><ArticleId IdType="pmc">PMC9552938</ArticleId><ArticleId IdType="pubmed">35697880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019 doi: 10.1093/brain/awz099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz099</ArticleId><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Reply: LATE to the PART-y. Brain. 2019;142:e48. doi: 10.1093/brain/awz226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz226</ArticleId><ArticleId IdType="pmc">PMC6931389</ArticleId><ArticleId IdType="pubmed">31359039</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Gal Z, Wang WX, Niedowicz DM, Artiushin SC, Wycoff S, et al. TDP-43 proteinopathy in aging: Associations with risk-associated gene variants and with brain parenchymal thyroid hormone levels. Neurobiol Dis. 2019;125:67&#x2013;76. doi: 10.1016/j.nbd.2019.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.01.013</ArticleId><ArticleId IdType="pmc">PMC6696921</ArticleId><ArticleId IdType="pubmed">30682540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 2011;134:1506&#x2013;1518. doi: 10.1093/brain/awr053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr053</ArticleId><ArticleId IdType="pmc">PMC3097889</ArticleId><ArticleId IdType="pubmed">21596774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Smith CD, Abner EL, Wilfred BJ, Wang WX, Neltner JH, et al. Hippocampal sclerosis of aging, a prevalent and high-morbidity brain disease. Acta Neuropathol. 2013;126:161&#x2013;177. doi: 10.1007/s00401-013-1154-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1154-1</ArticleId><ArticleId IdType="pmc">PMC3889169</ArticleId><ArticleId IdType="pubmed">23864344</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Frick P, Paron F, Kosten J, Buratti E, Mackenzie IR. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes. Acta Neuropathol. 2020;140:645&#x2013;658. doi: 10.1007/s00401-020-02207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02207-w</ArticleId><ArticleId IdType="pmc">PMC7547034</ArticleId><ArticleId IdType="pubmed">32778941</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Lee EB, Mackenzie IR. Frontotemporal lobar degeneration TDP-43-immunoreactive pathological subtypes: clinical and mechanistic significance. Adv Exp Med Biol. 2021;1281:201&#x2013;217. doi: 10.1007/978-3-030-51140-1_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-51140-1_13</ArticleId><ArticleId IdType="pmc">PMC8183578</ArticleId><ArticleId IdType="pubmed">33433877</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen ML, Huie EZ, Whitmer RA, George KM, Dugger BN. Neuropathology studies of dementia in US persons other than non-hispanic whites. Free Neuropathol. 2022 doi: 10.17879/freeneuropathology-2022-3795.</Citation><ArticleIdList><ArticleId IdType="doi">10.17879/freeneuropathology-2022-3795</ArticleId><ArticleId IdType="pmc">PMC9007571</ArticleId><ArticleId IdType="pubmed">35425946</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Gefen T, Mao Q, Appin C, Kohler M, Walker J, et al. Revisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLD-TDP subtypes. Acta Neuropathol. 2019;138:167&#x2013;169. doi: 10.1007/s00401-019-02024-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02024-w</ArticleId><ArticleId IdType="pmc">PMC7186909</ArticleId><ArticleId IdType="pubmed">31065833</ArticleId></ArticleIdList></Reference><Reference><Citation>Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord. 2011;25:364&#x2013;368. doi: 10.1097/WAD.0b013e31820f8f50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31820f8f50</ArticleId><ArticleId IdType="pmc">PMC3107353</ArticleId><ArticleId IdType="pubmed">21346515</ArticleId></ArticleIdList></Reference><Reference><Citation>Postupna N, Rose SE, Gibbons LE, Coleman NM, Hellstern LL, Ritchie K, et al. The delayed neuropathological consequences of traumatic brain injury in a community-based sample. Front Neurol. 2021;12:624696. doi: 10.3389/fneur.2021.624696.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.624696</ArticleId><ArticleId IdType="pmc">PMC8008107</ArticleId><ArticleId IdType="pubmed">33796061</ArticleId></ArticleIdList></Reference><Reference><Citation>Power MC, Mormino E, Soldan A, James BD, Yu L, Armstrong NM, et al. Combined neuropathological pathways account for age-related risk of dementia. Ann Neurol. 2018;84:10&#x2013;22. doi: 10.1002/ana.25246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25246</ArticleId><ArticleId IdType="pmc">PMC6119518</ArticleId><ArticleId IdType="pubmed">29944741</ArticleId></ArticleIdList></Reference><Reference><Citation>Prater KE, Latimer CS, Jayadev S. Glial TDP-43 and TDP-43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes. Glia. 2022;70:239&#x2013;255. doi: 10.1002/glia.24096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.24096</ArticleId><ArticleId IdType="pmc">PMC8722378</ArticleId><ArticleId IdType="pubmed">34558120</ArticleId></ArticleIdList></Reference><Reference><Citation>Riku Y, Iwasaki Y, Ishigaki S, Akagi A, Hasegawa M, Nishioka K, et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. Brain. 2022 doi: 10.1093/brain/awac091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac091</ArticleId><ArticleId IdType="pubmed">35274674</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Corrada MM, Kovacs GG, Dominique M, Caswell C, Xie SX, et al. Non-Alzheimer&#x2019;s contributions to dementia and cognitive resilience in the 90+ study. Acta Neuropathol. 2018 doi: 10.1007/s00401-018-1872-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1872-5</ArticleId><ArticleId IdType="pmc">PMC6534149</ArticleId><ArticleId IdType="pubmed">29916037</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, Zhang P, Xie SX, Suh E, et al. Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain. 2020;143:2844&#x2013;2857. doi: 10.1093/brain/awaa219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa219</ArticleId><ArticleId IdType="pmc">PMC7526723</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Richardson H, Xie SX, Suh E, Van Deerlin VM, Alfaro B, et al. The development and convergence of co-pathologies in Alzheimer&#x2019;s disease. Brain. 2021;144:953&#x2013;962. doi: 10.1093/brain/awaa438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa438</ArticleId><ArticleId IdType="pmc">PMC8041349</ArticleId><ArticleId IdType="pubmed">33449993</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuwa M, Adachi T, Suzuki Y, Yoshida K, Fukuda H, Miura H, et al. First Japanese autopsy case showing LRRK2 mutation G2019S and TDP-43 proteinopathy. Parkinsonism Relat Disord. 2021;91:85&#x2013;87. doi: 10.1016/j.parkreldis.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2021.09.009</ArticleId><ArticleId IdType="pubmed">34543853</ArticleId></ArticleIdList></Reference><Reference><Citation>Saveri P, Magri S, Maderna E, Balistreri F, Lombardi R, Ciano C, et al. DNAJB2-related Charcot-Marie-Tooth disease type 2: pathomechanism insights and phenotypic spectrum widening. Eur J Neurol. 2022;29:2056&#x2013;2065. doi: 10.1111/ene.15326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15326</ArticleId><ArticleId IdType="pmc">PMC9314055</ArticleId><ArticleId IdType="pubmed">35286755</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnov DS, Salmon DP, Galasko D, Edland SD, Pizzo DP, Goodwill V, et al. TDP-43 pathology exacerbates cognitive decline in primary age-related tauopathy. Ann neurol. 2022 doi: 10.1002/ana.26438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26438</ArticleId><ArticleId IdType="pmc">PMC9391297</ArticleId><ArticleId IdType="pubmed">35696592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer W. Erkrankung des Ammon&#x2019;s horn als aetiologis ches moment der epilepsien. Arch Psychiatr Nurs. 1880;10:631&#x2013;675. doi: 10.1007/BF02224538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02224538</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C, et al. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain. 2015;138:3110&#x2013;3122. doi: 10.1093/brain/awv220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv220</ArticleId><ArticleId IdType="pubmed">26231953</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazwar M, Evia AM, Tamhane AA, Ridwan AR, Leurgans SE, Bennett DA, et al. Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is associated with lower R2 relaxation rate: an ex-vivo MRI and pathology investigation. Neurobiol Aging. 2022;117:128&#x2013;138. doi: 10.1016/j.neurobiolaging.2022.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2022.05.009</ArticleId><ArticleId IdType="pmc">PMC9667705</ArticleId><ArticleId IdType="pubmed">35728463</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJ, Rozemuller AJ, Braak H, et al. Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. Acta Neuropathol. 2011;122:577&#x2013;589. doi: 10.1007/s00401-011-0871-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0871-6</ArticleId><ArticleId IdType="pubmed">21935637</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800. doi: 10.1212/WNL.58.12.1791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.58.12.1791</ArticleId><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, von Arnim C, Griffin WS, Yamaguchi H, Mrak RE, Attems J, et al. Pathology of clinical and preclinical Alzheimer&#x2019;s disease. Eur Arch Psychiatry Clin Neurosci. 2013;263(Suppl 2):S137&#x2013;145. doi: 10.1007/s00406-013-0449-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-013-0449-5</ArticleId><ArticleId IdType="pubmed">24077890</ArticleId></ArticleIdList></Reference><Reference><Citation>Thom M. Hippocampal sclerosis: progress since Sommer. Brain Pathol. 2009;19:565&#x2013;572. doi: 10.1111/j.1750-3639.2008.00201.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2008.00201.x</ArticleId><ArticleId IdType="pmc">PMC8094764</ArticleId><ArticleId IdType="pubmed">18761661</ArticleId></ArticleIdList></Reference><Reference><Citation>Tome SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M, et al. Distinct molecular patterns of TDP-43 pathology in Alzheimer&#x2019;s disease: relationship with clinical phenotypes. Acta Neuropathol Commun. 2020;8:61. doi: 10.1186/s40478-020-00934-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00934-5</ArticleId><ArticleId IdType="pmc">PMC7189555</ArticleId><ArticleId IdType="pubmed">32349792</ArticleId></ArticleIdList></Reference><Reference><Citation>Trieu T, Sajjadi SA, Kawas CH, Nelson PT, Corrada MM. Risk factors of hippocampal sclerosis in the oldest old: the 90+ study. Neurology. 2018;91:e1788&#x2013;e1798. doi: 10.1212/WNL.0000000000006455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006455</ArticleId><ArticleId IdType="pmc">PMC6251605</ArticleId><ArticleId IdType="pubmed">30315072</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Kawas CH, Chang CK, Folstein MF, Hedreen JC. Lack of association of the apoE4 allele with hippocampal sclerosis dementia. Neurosci Lett. 1996;204:138&#x2013;140. doi: 10.1016/0304-3940(96)12331-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(96)12331-4</ArticleId><ArticleId IdType="pubmed">8929997</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A, et al. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun. 2015;3:35. doi: 10.1186/s40478-015-0215-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0215-1</ArticleId><ArticleId IdType="pmc">PMC4473839</ArticleId><ArticleId IdType="pubmed">26091809</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura MT, Robinson JL, Cousins KAQ, Tropea TF, Kargilis DC, McBride JD, et al. Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathol. 2021 doi: 10.1007/s00401-021-02383-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02383-3</ArticleId><ArticleId IdType="pmc">PMC9136643</ArticleId><ArticleId IdType="pubmed">34854996</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67:555&#x2013;564. doi: 10.1097/NEN.0b013e31817713b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, et al. Concomitant TAR-DNA-binding in Alzheimer disease and protein 43 pathology is present corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67:555&#x2013;564. doi: 10.1097/NEN.0b013e31817713b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, Engelborghs S, van der Zee J, Van Broeckhoven C. Genotype-phenotype links in frontotemporal lobar degeneration. Nat Rev Neurol. 2018;14:363&#x2013;378. doi: 10.1038/s41582-018-0009-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0009-8</ArticleId><ArticleId IdType="pubmed">29777184</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Schoor E, Koper MJ, Ospitalieri S, Dedeene L, Tome SO, Vandenberghe R, et al. Necrosome-positive granulovacuolar degeneration is associated with TDP-43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathol Appl Neurobiol. 2021;47:328&#x2013;345. doi: 10.1111/nan.12668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12668</ArticleId><ArticleId IdType="pubmed">32949047</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Daniels CM, Goldman JE, Trojanowski JQ, Lee VM, Messing A. Astrocytic TDP-43 pathology in Alexander disease. J Neurosci. 2014;34:6448&#x2013;6458. doi: 10.1523/JNEUROSCI.0248-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0248-14.2014</ArticleId><ArticleId IdType="pmc">PMC4012304</ArticleId><ArticleId IdType="pubmed">24806671</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SJ, Guo Y, Ervin JF, Lusk JB, Luo S. Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old. Acta Neuropathol. 2022;144:45&#x2013;57. doi: 10.1007/s00401-022-02432-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-022-02432-5</ArticleId><ArticleId IdType="pubmed">35551470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Flory M, Kuchna I, Nowicki K, Wegiel J, Ma SY, et al. Developmental deficits and staging of dynamics of age associated Alzheimer&#x2019;s disease neurodegeneration and neuronal loss in subjects with Down syndrome. Acta Neuropathol Commun. 2022;10:2. doi: 10.1186/s40478-021-01300-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-021-01300-9</ArticleId><ArticleId IdType="pmc">PMC8728914</ArticleId><ArticleId IdType="pubmed">34983655</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, et al. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia aging study participants. Ann NY Acad Sci. 2002;977:9&#x2013;23. doi: 10.1111/j.1749-6632.2002.tb04794.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2002.tb04794.x</ArticleId><ArticleId IdType="pubmed">12480729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Dickson DW, Stoessl AJ, Tsuboi Y, Chapon F, Gutmann L, et al. Pallidonigral TDP-43 pathology in perry syndrome. Parkinsonism Relat Disord. 2009;15:281&#x2013;286. doi: 10.1016/j.parkreldis.2008.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2008.07.005</ArticleId><ArticleId IdType="pmc">PMC2693935</ArticleId><ArticleId IdType="pubmed">18723384</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita R, Beck G, Yonenobu Y, Inoue K, Mitsutake A, Ishiura H, et al. TDP-43 proteinopathy presenting with typical symptoms of Parkinson&#x2019;s disease. Mov Disord. 2022 doi: 10.1002/mds.29048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.29048</ArticleId><ArticleId IdType="pubmed">35531755</ArticleId></ArticleIdList></Reference><Reference><Citation>Zabar Y, Carson KA, Troncoso JC, Kawas CH. Dementia due to hippocampal sclerosis: clinical features and comparison to Alzheimer&#x2019;s disease. Neurology. 1998;50(4):A59&#x2013;A60.</Citation></Reference><Reference><Citation>Zarow C, Sitzer TE, Chui HC. Understanding hippocampal sclerosis in the elderly: epidemiology, characterization, and diagnostic issues. Curr Neurol Neurosci Rep. 2008;8:363&#x2013;370. doi: 10.1007/s11910-008-0057-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-008-0057-3</ArticleId><ArticleId IdType="pubmed">18713571</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Vinters HV, Ellis WG, Weiner MW, Mungas D, White L, et al. Correlates of hippocampal neuron number in Alzheimer&#x2019;s disease and ischemic vascular dementia. Ann Neurol. 2005;57:896&#x2013;903. doi: 10.1002/ana.20503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20503</ArticleId><ArticleId IdType="pmc">PMC1851673</ArticleId><ArticleId IdType="pubmed">15929035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Weiner MW, Ellis WG, Chui HC. Prevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample. Brain Behav. 2012;2:435&#x2013;442. doi: 10.1002/brb3.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.66</ArticleId><ArticleId IdType="pmc">PMC3432966</ArticleId><ArticleId IdType="pubmed">22950047</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Sun B, Wang X, Lu H, Shao F, Rozemuller AJM, et al. Phosphorylated TDP-43 staging of primary age-related tauopathy. Neurosci Bull. 2018 doi: 10.1007/s12264-018-0300-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-018-0300-0</ArticleId><ArticleId IdType="pmc">PMC6426920</ArticleId><ArticleId IdType="pubmed">30382507</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>